Therapeutic Effect of Interleukin-23 p19 RNA Interference in Mice With Experimental Colitis / 胃肠病学
Chinese Journal of Gastroenterology
;
(12): 10-16, 2019.
Artigo
em Chinês
| WPRIM
| ID: wpr-861883
ABSTRACT
Background:
Inflammatory bowel disease (IBD) is an autoimmune bowel disease with poor clinical outcome. Proinflammatory cytokines are the main targets of biological therapies. Interleukin-23 (IL-23) is a key factor in IBD pathogenesis. Monoclonal antibodies against subunit of IL-23 have been reported to have therapeutic effects.Aims:
To investigate the therapeutic effect of IL-23 RNA interference in mice with experimental colitis and the underlying mechanism.Methods:
2,4,6-trinitrobenzenesulfonic acid (TNBS) enema was used to induce experimental colitis in mice, which were then injected with IL-23 p19 shRNA lentivirus or control shRNA lentivirus through caudal vein. Mice without lentivirus injection were served as model controls. After 2 weeks, disease activity index and histopathological inflammatory score, serum and colon tissue IL-23, IL-17 and tumor necrosis factor-α (TNF-α) expressions, as well as colon tissue Th17 cells were detected and compared.Results:
IL-23 p19 shRNA therapy significantly reduced disease activity index and histopathological inflammatory score in mice with experimental colitis (P<0.05). By inhibiting IL-23 expression, IL-23 p19 shRNA suppressed further the colon tissue Th17 cells and subsequently reduced systemic and colon tissue IL-17 and TNF-α expressions significantly (P<0.05).Conclusions:
IL-23 RNA interference has therapeutic effect in mice with experimental colitis. The mechanism lies in suppression of Th17 cells and its effector cytokine IL-17.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Tipo de estudo:
Estudo prognóstico
Idioma:
Chinês
Revista:
Chinese Journal of Gastroenterology
Ano de publicação:
2019
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS